Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial
Deeper insight is needed on how monoclonal antibodies (mAbs) affect vaccine-mediated immune responses when targeting the same protein. We describe the first prospective randomised trial designed to understand mAb-mediated alterations in vaccine-induced immune responses to SARS-CoV-2 spike protein ep...
Saved in:
| Published in | The Lancet infectious diseases Vol. 25; no. 1; pp. 52 - 67 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Ltd
01.01.2025
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Deeper insight is needed on how monoclonal antibodies (mAbs) affect vaccine-mediated immune responses when targeting the same protein. We describe the first prospective randomised trial designed to understand mAb-mediated alterations in vaccine-induced immune responses to SARS-CoV-2 spike protein epitopes.
This randomised, open-label, parallel-group study assessed the potential interaction of a mAb combination, casirivimab and imdevimab, with a vaccine, Moderna's mRNA-1273, in healthy SARS-CoV-2 immunologically naive, seronegative adults at six centres in the USA. Participants were randomly assigned (per prespecified randomisation ratios within enrolment waves) according to a computer-generated randomisation scheme, stratified by age (<65 years and ≥65 years), to various intravenous or subcutaneous doses of casirivimab and imdevimab before, after, or at the same time as mRNA-1273 or to mRNA-1273 only. The doses of casirivimab and imdevimab were chosen to mimic various time intervals between receipt of 1200 mg of the mAb and the first dose of a primary series with mRNA-1273. The primary endpoint was vaccine-induced 50% inhibitory dilution neutralising antibody titres to SARS-CoV-2 spike protein, 56 days after the first vaccination. Secondary endpoints included vaccine-induced total antibodies to SARS-CoV-2 antigens and incidence of treatment-emergent adverse events. Exploratory endpoints included blood-derived T-cell and B-cell responses. The per-protocol set was used for the analysis of the primary endpoint and included all randomly assigned participants who received both doses of the vaccine and completed the injection or infusion of casirivimab and imdevimab per protocol, had no evidence of SARS-CoV-2 infection in the past or in the 56 days after the first dose of vaccine, and did not receive any intervention outside of the study that could alter the immune response. Safety was assessed in the safety analysis set, which included all randomly assigned participants who had received one or more doses of mRNA-1273 or any study drug, and analysed based on treatment received. The study is registered with ClinicalTrials.gov, NCT04852978, and is complete.
Between April 29, 2021, and Nov 21, 2022, 807 participants were assessed for eligibility and 295 were randomly assigned. 293 participants were included in the safety analysis set and 260 were included in the per-protocol set. All vaccinated participants developed neutralising antibodies to SARS-CoV-2, with median titres above the published protective threshold (100 IU/mL) against the SARS-CoV-2 D614G variant (considered a reference strain at the time the initial COVID-19 vaccines were developed). Titres were decreased up to 4-fold (median titres 280–450 IU/mL for casirivimab and imdevimab vs 1160 IU/mL for vaccine only on day 56) when casirivimab and imdevimab was given 85 days or less before vaccination (150–1200 mg intravenously) or co-administered subcutaneously (600 mg or 1200 mg) with vaccination. Minimal reduction in neutralisation titres was observed in the 48 mg and 12 mg intravenous groups, corresponding to receipt of casirivimab and imdevimab 113 days and 169 days, respectively, before vaccination, and when administering the vaccine 6 days before the mAb. Across all groups, mAbs had a minimal effect on vaccine-induced total antibodies and T-cell responses to the spike protein. Casirivimab and imdevimab plus mRNA-1273 was generally well tolerated; a slight increase in treatment-emergent adverse events was observed in the casirivimab and imdevimab plus vaccine groups versus the vaccine-only group.
Casirivimab and imdevimab administration before or at the time of COVID-19 vaccination reduced the elicitation of SARS-CoV-2 neutralising antibodies, but minimal effect was observed when vaccination occurred before mAb administration. Although the clinical significance of this decrease in neutralisation is unclear, this evidence suggests that further investigation of potential interactions could be warranted before concurrent clinical use of mAbs and vaccines targeting the same viral proteins as their main modes of action for the prevention or treatment of infectious diseases.
Regeneron Pharmaceuticals and F Hoffmann-La Roche. |
|---|---|
| AbstractList | Deeper insight is needed on how monoclonal antibodies (mAbs) affect vaccine-mediated immune responses when targeting the same protein. We describe the first prospective randomised trial designed to understand mAb-mediated alterations in vaccine-induced immune responses to SARS-CoV-2 spike protein epitopes.
This randomised, open-label, parallel-group study assessed the potential interaction of a mAb combination, casirivimab and imdevimab, with a vaccine, Moderna's mRNA-1273, in healthy SARS-CoV-2 immunologically naive, seronegative adults at six centres in the USA. Participants were randomly assigned (per prespecified randomisation ratios within enrolment waves) according to a computer-generated randomisation scheme, stratified by age (<65 years and ≥65 years), to various intravenous or subcutaneous doses of casirivimab and imdevimab before, after, or at the same time as mRNA-1273 or to mRNA-1273 only. The doses of casirivimab and imdevimab were chosen to mimic various time intervals between receipt of 1200 mg of the mAb and the first dose of a primary series with mRNA-1273. The primary endpoint was vaccine-induced 50% inhibitory dilution neutralising antibody titres to SARS-CoV-2 spike protein, 56 days after the first vaccination. Secondary endpoints included vaccine-induced total antibodies to SARS-CoV-2 antigens and incidence of treatment-emergent adverse events. Exploratory endpoints included blood-derived T-cell and B-cell responses. The per-protocol set was used for the analysis of the primary endpoint and included all randomly assigned participants who received both doses of the vaccine and completed the injection or infusion of casirivimab and imdevimab per protocol, had no evidence of SARS-CoV-2 infection in the past or in the 56 days after the first dose of vaccine, and did not receive any intervention outside of the study that could alter the immune response. Safety was assessed in the safety analysis set, which included all randomly assigned participants who had received one or more doses of mRNA-1273 or any study drug, and analysed based on treatment received. The study is registered with ClinicalTrials.gov, NCT04852978, and is complete.
Between April 29, 2021, and Nov 21, 2022, 807 participants were assessed for eligibility and 295 were randomly assigned. 293 participants were included in the safety analysis set and 260 were included in the per-protocol set. All vaccinated participants developed neutralising antibodies to SARS-CoV-2, with median titres above the published protective threshold (100 IU/mL) against the SARS-CoV-2 D614G variant (considered a reference strain at the time the initial COVID-19 vaccines were developed). Titres were decreased up to 4-fold (median titres 280-450 IU/mL for casirivimab and imdevimab vs 1160 IU/mL for vaccine only on day 56) when casirivimab and imdevimab was given 85 days or less before vaccination (150-1200 mg intravenously) or co-administered subcutaneously (600 mg or 1200 mg) with vaccination. Minimal reduction in neutralisation titres was observed in the 48 mg and 12 mg intravenous groups, corresponding to receipt of casirivimab and imdevimab 113 days and 169 days, respectively, before vaccination, and when administering the vaccine 6 days before the mAb. Across all groups, mAbs had a minimal effect on vaccine-induced total antibodies and T-cell responses to the spike protein. Casirivimab and imdevimab plus mRNA-1273 was generally well tolerated; a slight increase in treatment-emergent adverse events was observed in the casirivimab and imdevimab plus vaccine groups versus the vaccine-only group.
Casirivimab and imdevimab administration before or at the time of COVID-19 vaccination reduced the elicitation of SARS-CoV-2 neutralising antibodies, but minimal effect was observed when vaccination occurred before mAb administration. Although the clinical significance of this decrease in neutralisation is unclear, this evidence suggests that further investigation of potential interactions could be warranted before concurrent clinical use of mAbs and vaccines targeting the same viral proteins as their main modes of action for the prevention or treatment of infectious diseases.
Regeneron Pharmaceuticals and F Hoffmann-La Roche. Summary Background Deeper insight is needed on how monoclonal antibodies (mAbs) affect vaccine-mediated immune responses when targeting the same protein. We describe the first prospective randomised trial designed to understand mAb-mediated alterations in vaccine-induced immune responses to SARS-CoV-2 spike protein epitopes. Methods This randomised, open-label, parallel-group study assessed the potential interaction of a mAb combination, casirivimab and imdevimab, with a vaccine, Moderna's mRNA-1273, in healthy SARS-CoV-2 immunologically naive, seronegative adults at six centres in the USA. Participants were randomly assigned (per prespecified randomisation ratios within enrolment waves) according to a computer-generated randomisation scheme, stratified by age (<65 years and ≥65 years), to various intravenous or subcutaneous doses of casirivimab and imdevimab before, after, or at the same time as mRNA-1273 or to mRNA-1273 only. The doses of casirivimab and imdevimab were chosen to mimic various time intervals between receipt of 1200 mg of the mAb and the first dose of a primary series with mRNA-1273. The primary endpoint was vaccine-induced 50% inhibitory dilution neutralising antibody titres to SARS-CoV-2 spike protein, 56 days after the first vaccination. Secondary endpoints included vaccine-induced total antibodies to SARS-CoV-2 antigens and incidence of treatment-emergent adverse events. Exploratory endpoints included blood-derived T-cell and B-cell responses. The per-protocol set was used for the analysis of the primary endpoint and included all randomly assigned participants who received both doses of the vaccine and completed the injection or infusion of casirivimab and imdevimab per protocol, had no evidence of SARS-CoV-2 infection in the past or in the 56 days after the first dose of vaccine, and did not receive any intervention outside of the study that could alter the immune response. Safety was assessed in the safety analysis set, which included all randomly assigned participants who had received one or more doses of mRNA-1273 or any study drug, and analysed based on treatment received. The study is registered with ClinicalTrials.gov, NCT04852978, and is complete. Findings Between April 29, 2021, and Nov 21, 2022, 807 participants were assessed for eligibility and 295 were randomly assigned. 293 participants were included in the safety analysis set and 260 were included in the per-protocol set. All vaccinated participants developed neutralising antibodies to SARS-CoV-2, with median titres above the published protective threshold (100 IU/mL) against the SARS-CoV-2 D614G variant (considered a reference strain at the time the initial COVID-19 vaccines were developed). Titres were decreased up to 4-fold (median titres 280–450 IU/mL for casirivimab and imdevimab vs 1160 IU/mL for vaccine only on day 56) when casirivimab and imdevimab was given 85 days or less before vaccination (150–1200 mg intravenously) or co-administered subcutaneously (600 mg or 1200 mg) with vaccination. Minimal reduction in neutralisation titres was observed in the 48 mg and 12 mg intravenous groups, corresponding to receipt of casirivimab and imdevimab 113 days and 169 days, respectively, before vaccination, and when administering the vaccine 6 days before the mAb. Across all groups, mAbs had a minimal effect on vaccine-induced total antibodies and T-cell responses to the spike protein. Casirivimab and imdevimab plus mRNA-1273 was generally well tolerated; a slight increase in treatment-emergent adverse events was observed in the casirivimab and imdevimab plus vaccine groups versus the vaccine-only group. Interpretation Casirivimab and imdevimab administration before or at the time of COVID-19 vaccination reduced the elicitation of SARS-CoV-2 neutralising antibodies, but minimal effect was observed when vaccination occurred before mAb administration. Although the clinical significance of this decrease in neutralisation is unclear, this evidence suggests that further investigation of potential interactions could be warranted before concurrent clinical use of mAbs and vaccines targeting the same viral proteins as their main modes of action for the prevention or treatment of infectious diseases. Funding Regeneron Pharmaceuticals and F Hoffmann-La Roche. Deeper insight is needed on how monoclonal antibodies (mAbs) affect vaccine-mediated immune responses when targeting the same protein. We describe the first prospective randomised trial designed to understand mAb-mediated alterations in vaccine-induced immune responses to SARS-CoV-2 spike protein epitopes.BACKGROUNDDeeper insight is needed on how monoclonal antibodies (mAbs) affect vaccine-mediated immune responses when targeting the same protein. We describe the first prospective randomised trial designed to understand mAb-mediated alterations in vaccine-induced immune responses to SARS-CoV-2 spike protein epitopes.This randomised, open-label, parallel-group study assessed the potential interaction of a mAb combination, casirivimab and imdevimab, with a vaccine, Moderna's mRNA-1273, in healthy SARS-CoV-2 immunologically naive, seronegative adults at six centres in the USA. Participants were randomly assigned (per prespecified randomisation ratios within enrolment waves) according to a computer-generated randomisation scheme, stratified by age (<65 years and ≥65 years), to various intravenous or subcutaneous doses of casirivimab and imdevimab before, after, or at the same time as mRNA-1273 or to mRNA-1273 only. The doses of casirivimab and imdevimab were chosen to mimic various time intervals between receipt of 1200 mg of the mAb and the first dose of a primary series with mRNA-1273. The primary endpoint was vaccine-induced 50% inhibitory dilution neutralising antibody titres to SARS-CoV-2 spike protein, 56 days after the first vaccination. Secondary endpoints included vaccine-induced total antibodies to SARS-CoV-2 antigens and incidence of treatment-emergent adverse events. Exploratory endpoints included blood-derived T-cell and B-cell responses. The per-protocol set was used for the analysis of the primary endpoint and included all randomly assigned participants who received both doses of the vaccine and completed the injection or infusion of casirivimab and imdevimab per protocol, had no evidence of SARS-CoV-2 infection in the past or in the 56 days after the first dose of vaccine, and did not receive any intervention outside of the study that could alter the immune response. Safety was assessed in the safety analysis set, which included all randomly assigned participants who had received one or more doses of mRNA-1273 or any study drug, and analysed based on treatment received. The study is registered with ClinicalTrials.gov, NCT04852978, and is complete.METHODSThis randomised, open-label, parallel-group study assessed the potential interaction of a mAb combination, casirivimab and imdevimab, with a vaccine, Moderna's mRNA-1273, in healthy SARS-CoV-2 immunologically naive, seronegative adults at six centres in the USA. Participants were randomly assigned (per prespecified randomisation ratios within enrolment waves) according to a computer-generated randomisation scheme, stratified by age (<65 years and ≥65 years), to various intravenous or subcutaneous doses of casirivimab and imdevimab before, after, or at the same time as mRNA-1273 or to mRNA-1273 only. The doses of casirivimab and imdevimab were chosen to mimic various time intervals between receipt of 1200 mg of the mAb and the first dose of a primary series with mRNA-1273. The primary endpoint was vaccine-induced 50% inhibitory dilution neutralising antibody titres to SARS-CoV-2 spike protein, 56 days after the first vaccination. Secondary endpoints included vaccine-induced total antibodies to SARS-CoV-2 antigens and incidence of treatment-emergent adverse events. Exploratory endpoints included blood-derived T-cell and B-cell responses. The per-protocol set was used for the analysis of the primary endpoint and included all randomly assigned participants who received both doses of the vaccine and completed the injection or infusion of casirivimab and imdevimab per protocol, had no evidence of SARS-CoV-2 infection in the past or in the 56 days after the first dose of vaccine, and did not receive any intervention outside of the study that could alter the immune response. Safety was assessed in the safety analysis set, which included all randomly assigned participants who had received one or more doses of mRNA-1273 or any study drug, and analysed based on treatment received. The study is registered with ClinicalTrials.gov, NCT04852978, and is complete.Between April 29, 2021, and Nov 21, 2022, 807 participants were assessed for eligibility and 295 were randomly assigned. 293 participants were included in the safety analysis set and 260 were included in the per-protocol set. All vaccinated participants developed neutralising antibodies to SARS-CoV-2, with median titres above the published protective threshold (100 IU/mL) against the SARS-CoV-2 D614G variant (considered a reference strain at the time the initial COVID-19 vaccines were developed). Titres were decreased up to 4-fold (median titres 280-450 IU/mL for casirivimab and imdevimab vs 1160 IU/mL for vaccine only on day 56) when casirivimab and imdevimab was given 85 days or less before vaccination (150-1200 mg intravenously) or co-administered subcutaneously (600 mg or 1200 mg) with vaccination. Minimal reduction in neutralisation titres was observed in the 48 mg and 12 mg intravenous groups, corresponding to receipt of casirivimab and imdevimab 113 days and 169 days, respectively, before vaccination, and when administering the vaccine 6 days before the mAb. Across all groups, mAbs had a minimal effect on vaccine-induced total antibodies and T-cell responses to the spike protein. Casirivimab and imdevimab plus mRNA-1273 was generally well tolerated; a slight increase in treatment-emergent adverse events was observed in the casirivimab and imdevimab plus vaccine groups versus the vaccine-only group.FINDINGSBetween April 29, 2021, and Nov 21, 2022, 807 participants were assessed for eligibility and 295 were randomly assigned. 293 participants were included in the safety analysis set and 260 were included in the per-protocol set. All vaccinated participants developed neutralising antibodies to SARS-CoV-2, with median titres above the published protective threshold (100 IU/mL) against the SARS-CoV-2 D614G variant (considered a reference strain at the time the initial COVID-19 vaccines were developed). Titres were decreased up to 4-fold (median titres 280-450 IU/mL for casirivimab and imdevimab vs 1160 IU/mL for vaccine only on day 56) when casirivimab and imdevimab was given 85 days or less before vaccination (150-1200 mg intravenously) or co-administered subcutaneously (600 mg or 1200 mg) with vaccination. Minimal reduction in neutralisation titres was observed in the 48 mg and 12 mg intravenous groups, corresponding to receipt of casirivimab and imdevimab 113 days and 169 days, respectively, before vaccination, and when administering the vaccine 6 days before the mAb. Across all groups, mAbs had a minimal effect on vaccine-induced total antibodies and T-cell responses to the spike protein. Casirivimab and imdevimab plus mRNA-1273 was generally well tolerated; a slight increase in treatment-emergent adverse events was observed in the casirivimab and imdevimab plus vaccine groups versus the vaccine-only group.Casirivimab and imdevimab administration before or at the time of COVID-19 vaccination reduced the elicitation of SARS-CoV-2 neutralising antibodies, but minimal effect was observed when vaccination occurred before mAb administration. Although the clinical significance of this decrease in neutralisation is unclear, this evidence suggests that further investigation of potential interactions could be warranted before concurrent clinical use of mAbs and vaccines targeting the same viral proteins as their main modes of action for the prevention or treatment of infectious diseases.INTERPRETATIONCasirivimab and imdevimab administration before or at the time of COVID-19 vaccination reduced the elicitation of SARS-CoV-2 neutralising antibodies, but minimal effect was observed when vaccination occurred before mAb administration. Although the clinical significance of this decrease in neutralisation is unclear, this evidence suggests that further investigation of potential interactions could be warranted before concurrent clinical use of mAbs and vaccines targeting the same viral proteins as their main modes of action for the prevention or treatment of infectious diseases.Regeneron Pharmaceuticals and F Hoffmann-La Roche.FUNDINGRegeneron Pharmaceuticals and F Hoffmann-La Roche. |
| Author | Isa, Flonza Baum, Alina Thakur, Mazhar Petro, Christopher D Hutter, Julia Rosenthal, Mark J Patel, Aloki H Dakin, Paula Polakowski, Laura McElrath, M Juliana Hamilton, Jennifer D Irvin, Susan C Cohen, Kristen W Brackin, Taylor Trbovic, Caryn F Kyratsous, Christos A Marovich, Mary Odeh, Ahmad J Hellman, Caleb A DiCioccio, A Thomas Hooper, Andrea T Herman, Gary A Fakih, Faisal A Heirman, Ingeborg Olenchock, Benjamin A Ganguly, Samit Williams, LaTonya D Musser, Bret Meyer, Jonathan Forleo-Neto, Eduardo Kim, Yunji Gonzalez Ortiz, Ana M Geba, Gregory P Konis, George Faria, Lori Tomaras, Georgia D De Rosa, Stephen C Yancopoulos, George D Turner, Kenneth C Kowal, Bari |
| Author_xml | – sequence: 1 givenname: Flonza surname: Isa fullname: Isa, Flonza email: flonza.isa@regeneron.com organization: Regeneron Pharmaceuticals, Tarrytown, NY, USA – sequence: 2 givenname: Ana M surname: Gonzalez Ortiz fullname: Gonzalez Ortiz, Ana M organization: Regeneron Pharmaceuticals, Tarrytown, NY, USA – sequence: 3 givenname: Jonathan surname: Meyer fullname: Meyer, Jonathan organization: Regeneron Pharmaceuticals, Tarrytown, NY, USA – sequence: 4 givenname: Jennifer D surname: Hamilton fullname: Hamilton, Jennifer D organization: Regeneron Pharmaceuticals, Tarrytown, NY, USA – sequence: 5 givenname: Benjamin A surname: Olenchock fullname: Olenchock, Benjamin A organization: Regeneron Pharmaceuticals, Tarrytown, NY, USA – sequence: 6 givenname: Taylor surname: Brackin fullname: Brackin, Taylor organization: Regeneron Pharmaceuticals, Tarrytown, NY, USA – sequence: 7 givenname: Samit surname: Ganguly fullname: Ganguly, Samit organization: Regeneron Pharmaceuticals, Tarrytown, NY, USA – sequence: 8 givenname: Eduardo surname: Forleo-Neto fullname: Forleo-Neto, Eduardo organization: Regeneron Pharmaceuticals, Tarrytown, NY, USA – sequence: 9 givenname: Lori surname: Faria fullname: Faria, Lori organization: Regeneron Pharmaceuticals, Tarrytown, NY, USA – sequence: 10 givenname: Ingeborg surname: Heirman fullname: Heirman, Ingeborg organization: Regeneron Pharmaceuticals, Tarrytown, NY, USA – sequence: 11 givenname: Mary surname: Marovich fullname: Marovich, Mary organization: National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA – sequence: 12 givenname: Julia surname: Hutter fullname: Hutter, Julia organization: National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA – sequence: 13 givenname: Laura surname: Polakowski fullname: Polakowski, Laura organization: National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA – sequence: 14 givenname: Susan C surname: Irvin fullname: Irvin, Susan C organization: Regeneron Pharmaceuticals, Tarrytown, NY, USA – sequence: 15 givenname: Mazhar surname: Thakur fullname: Thakur, Mazhar organization: Regeneron Pharmaceuticals, Tarrytown, NY, USA – sequence: 16 givenname: Andrea T surname: Hooper fullname: Hooper, Andrea T organization: Regeneron Pharmaceuticals, Tarrytown, NY, USA – sequence: 17 givenname: Alina surname: Baum fullname: Baum, Alina organization: Regeneron Pharmaceuticals, Tarrytown, NY, USA – sequence: 18 givenname: Christopher D surname: Petro fullname: Petro, Christopher D organization: Regeneron Pharmaceuticals, Tarrytown, NY, USA – sequence: 19 givenname: Faisal A surname: Fakih fullname: Fakih, Faisal A organization: Clinical Site Partners, d/b/a CSP Orlando, Winter Park, FL, USA – sequence: 20 givenname: M Juliana surname: McElrath fullname: McElrath, M Juliana organization: Fred Hutchinson Cancer Center, Seattle, WA, USA – sequence: 21 givenname: Stephen C surname: De Rosa fullname: De Rosa, Stephen C organization: Fred Hutchinson Cancer Center, Seattle, WA, USA – sequence: 22 givenname: Kristen W surname: Cohen fullname: Cohen, Kristen W organization: Fred Hutchinson Cancer Center, Seattle, WA, USA – sequence: 23 givenname: LaTonya D surname: Williams fullname: Williams, LaTonya D organization: Duke University School of Medicine, Durham, NC, USA – sequence: 24 givenname: Caleb A surname: Hellman fullname: Hellman, Caleb A organization: Duke University School of Medicine, Durham, NC, USA – sequence: 25 givenname: Ahmad J surname: Odeh fullname: Odeh, Ahmad J organization: Duke University School of Medicine, Durham, NC, USA – sequence: 26 givenname: Aloki H surname: Patel fullname: Patel, Aloki H organization: Duke University School of Medicine, Durham, NC, USA – sequence: 27 givenname: Georgia D surname: Tomaras fullname: Tomaras, Georgia D organization: Duke University School of Medicine, Durham, NC, USA – sequence: 28 givenname: Gregory P surname: Geba fullname: Geba, Gregory P organization: Regeneron Pharmaceuticals, Tarrytown, NY, USA – sequence: 29 givenname: Christos A surname: Kyratsous fullname: Kyratsous, Christos A organization: Regeneron Pharmaceuticals, Tarrytown, NY, USA – sequence: 30 givenname: Bret surname: Musser fullname: Musser, Bret organization: Regeneron Pharmaceuticals, Tarrytown, NY, USA – sequence: 31 givenname: George D surname: Yancopoulos fullname: Yancopoulos, George D organization: Regeneron Pharmaceuticals, Tarrytown, NY, USA – sequence: 32 givenname: Gary A surname: Herman fullname: Herman, Gary A organization: Regeneron Pharmaceuticals, Tarrytown, NY, USA – sequence: 33 givenname: Kenneth C surname: Turner fullname: Turner, Kenneth C – sequence: 34 givenname: Yunji surname: Kim fullname: Kim, Yunji – sequence: 35 givenname: George surname: Konis fullname: Konis, George – sequence: 36 givenname: Mark J surname: Rosenthal fullname: Rosenthal, Mark J – sequence: 37 givenname: Caryn F surname: Trbovic fullname: Trbovic, Caryn F – sequence: 38 givenname: Bari surname: Kowal fullname: Kowal, Bari – sequence: 39 givenname: A Thomas surname: DiCioccio fullname: DiCioccio, A Thomas – sequence: 40 givenname: Paula surname: Dakin fullname: Dakin, Paula |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39236733$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkl-L1DAUxYusuH_0IygBX1aYaJOm7XRFZBhXXVhc2NF9LWlyq1nTpCbtwHxhP4d3pqMP87JCoTfld08POec0OXLeQZI8Z-lrlrLizYqJMqNZWlXnXLxKU8EZzR4lJ_hZUCHy8mg3T8hxchrjfZqykqXiSXKcVTwryiw7SX5fti2ogfiWDKYz7vt2UjKaYNamkw2RThPTadifNDImDkEOxjsSwOKwBjJ40t1-WVDGy4wsb-6uPlBWkbVUyrgJxWc6AjVOjwo0WS1uV3Tp7ygnDkbUtCZuHUg3mMbrDcrH3rsI8YJI0gcfe7SKv5sR34OjVjZgZ6T_ISMQPiMBvfrORJRW3g3BW4vjEIy0T5PHrbQRnu3fZ8m3j5dfl5_p9c2nq-XimiohyoEKXZZ63ijgQstCa9YwkVXAZJPPIW91wbWUAjiopmqAqYLP5xKglG2bt_OyzM6S80kX3f4aIQ41-lFgrXTgx1hnmB3P0jTPEX15gN77MTh0h5SoiioXfI7Uiz01Nh3oug-YQ9jUfxNEIJ8AhfcTA7T_EJbW26bUu6bU2xrUXNS7ptTbvbcHe8oMu6gwCGMf3H4_bQNe5tpAqKMy4DBVEzCjWnvzoMK7AwVlsVpK2p-w-Y_9P1e17cs |
| CitedBy_id | crossref_primary_10_1080_22221751_2025_2471035 |
| Cites_doi | 10.1056/NEJMoa2116620 10.1126/scitranslmed.abn3041 10.1038/s41591-021-01540-1 10.1126/scitranslmed.abo6160 10.1007/s00251-023-01294-9 10.1126/science.abm3425 10.1016/S2213-2600(22)00180-1 10.1098/rstb.2014.0248 10.1001/jamanetworkopen.2022.25411 10.1056/NEJMoa2102685 10.1056/NEJMoa2028436 10.1056/NEJMoa2116414 10.1126/scitranslmed.abi9915 10.1001/jama.2021.24939 10.1038/s41467-023-39292-w 10.4155/bio-2021-0190 10.1056/NEJMoa2118542 10.1056/NEJMoa2109682 10.1126/scitranslmed.ade9078 10.1056/NEJMoa2022483 10.1126/sciimmunol.abi6950 10.1038/s41586-022-05609-w 10.1056/NEJMoa2119451 10.1056/NEJMoa2108163 10.1001/jama.2021.8828 10.1038/s41467-021-25479-6 |
| ContentType | Journal Article |
| Contributor | DiCioccio, A Thomas Rosenthal, Mark J Konis, George Trbovic, Caryn F Turner, Kenneth C Kowal, Bari Dakin, Paula Kim, Yunji |
| Contributor_xml | – sequence: 1 givenname: Kenneth C surname: Turner fullname: Turner, Kenneth C – sequence: 2 givenname: Yunji surname: Kim fullname: Kim, Yunji – sequence: 3 givenname: George surname: Konis fullname: Konis, George – sequence: 4 givenname: Mark J surname: Rosenthal fullname: Rosenthal, Mark J – sequence: 5 givenname: Caryn F surname: Trbovic fullname: Trbovic, Caryn F – sequence: 6 givenname: Bari surname: Kowal fullname: Kowal, Bari – sequence: 7 givenname: A Thomas surname: DiCioccio fullname: DiCioccio, A Thomas – sequence: 8 givenname: Paula surname: Dakin fullname: Dakin, Paula |
| Copyright | 2025 Elsevier Ltd Copyright © 2024. Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies. 2025. Elsevier Ltd |
| Copyright_xml | – notice: 2025 Elsevier Ltd – notice: Copyright © 2024. Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies. – notice: 2025. Elsevier Ltd |
| CorporateAuthor | Trial Working Group |
| CorporateAuthor_xml | – name: Trial Working Group |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 0TZ 3V. 7QL 7RV 7U9 7X7 7XB 88E 8AO 8C1 8C2 8FI 8FJ 8FK ABUWG AEUYN AFKRA BENPR C1K CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P M7N NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.1016/S1473-3099(24)00421-3 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Pharma and Biotech Premium PRO ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Nursing & Allied Health Database Virology and AIDS Abstracts Health & Medical Collection (ProQuest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Lancet Titles Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Database Suite (ProQuest) Environmental Sciences and Pollution Management ProQuest One Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni) Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Pharma and Biotech Premium PRO ProQuest One Academic Middle East (New) Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Pharma and Biotech Premium PRO MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1474-4457 |
| EndPage | 67 |
| ExternalDocumentID | 39236733 10_1016_S1473_3099_24_00421_3 S1473309924004213 |
| Genre | Randomized Controlled Trial Clinical Trial, Phase II Journal Article |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GrantInformation | Regeneron Pharmaceuticals and F Hoffmann-La Roche. |
| GroupedDBID | --- --K --M -RU ..I .1- .FO 0R~ 123 1B1 1P~ 1~5 29L 4.4 457 4G. 53G 5VS 6PF 7-5 71M 7RV 7X7 88E 8AO 8C1 8C2 8FI 8FJ AAAJQ AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AAQXK AARKO AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABJNI ABMAC ABMZM ABUWG ABWVN ACGFS ACIEU ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AEIPS AEKER AENEX AEUPX AEUYN AEVXI AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGEKW AGHFR AGQPQ AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CJTIS CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA HF~ HMCUK HVGLF HZ~ IHE J1W KOM M1P M41 MO0 N9A NAPCQ O-L O9- OD- OO. OZT P-8 P-9 P2P PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO R2- ROL RPZ SDG SEL SES SPCBC SSH SSI SSZ T5K TLN UKHRP UV1 WOW XBR Z5R 3V. AACTN AAYOK AFCTW AFKWA AJOXV ALIPV AMFUW RIG SDF AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 0TZ 7QL 7U9 7XB 8FK C1K H94 K9. M7N PKEHL PQEST PQUKI PRINS 7X8 |
| ID | FETCH-LOGICAL-c447t-4d77d8bce24da6dd1b1439e1ab58e5fd62daa4e2ecb9be1c6288aee7aff5f8773 |
| IEDL.DBID | 7X7 |
| ISSN | 1473-3099 1474-4457 |
| IngestDate | Tue Aug 05 11:11:19 EDT 2025 Wed Aug 13 06:49:10 EDT 2025 Wed Feb 19 01:58:16 EST 2025 Tue Jul 01 00:46:13 EDT 2025 Thu Apr 24 23:04:18 EDT 2025 Sat Feb 08 15:52:24 EST 2025 Tue Aug 26 16:38:54 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | Copyright © 2024. Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c447t-4d77d8bce24da6dd1b1439e1ab58e5fd62daa4e2ecb9be1c6288aee7aff5f8773 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| PMID | 39236733 |
| PQID | 3149695428 |
| PQPubID | 44001 |
| PageCount | 16 |
| ParticipantIDs | proquest_miscellaneous_3101230055 proquest_journals_3149695428 pubmed_primary_39236733 crossref_primary_10_1016_S1473_3099_24_00421_3 crossref_citationtrail_10_1016_S1473_3099_24_00421_3 elsevier_sciencedirect_doi_10_1016_S1473_3099_24_00421_3 elsevier_clinicalkey_doi_10_1016_S1473_3099_24_00421_3 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | January 2025 2025-01-00 2025-Jan 20250101 |
| PublicationDateYYYYMMDD | 2025-01-01 |
| PublicationDate_xml | – month: 01 year: 2025 text: January 2025 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: London |
| PublicationTitle | The Lancet infectious diseases |
| PublicationTitleAlternate | Lancet Infect Dis |
| PublicationYear | 2025 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Gilbert, Montefiori, McDermott (bib27) 2022; 375 Cohen, Nirula, Mulligan (bib16) 2021; 326 Montgomery, Hobbs, Padilla (bib14) 2022; 10 Levin, Ustianowski, De Wit (bib12) 2022; 386 Weinreich, Sivapalasingam, Norton (bib1) 2021; 385 (bib18) Feb 4, 2022 Benschop, Tuttle, Zhang (bib19) 2022; 14 Dougan, Nirula, Azizad (bib15) 2021; 385 (bib22) 2022 Schaefer-Babajew, Wang, Muecksch (bib21) 2023; 613 (bib8) 2021 Benkeser, Montefiori, McDermott (bib11) 2023; 15 Atmar, Lyke, Deming (bib29) 2022; 386 Irvin, Ganguly, Weiss (bib24) 2021; 13 O'Brien, Forleo-Neto, Sarkar (bib13) 2022; 327 Hammond, Leister-Tebbe, Gardner (bib5) 2022; 386 Greaney, Loes, Gentles (bib3) 2021; 13 Goel, Apostolidis, Painter (bib28) 2021; 6 Follmann, O'Brien, Fintzi (bib10) 2023; 14 (bib6) 2021 O'Brien, Forleo-Neto, Musser (bib2) 2021; 385 Zarnitsyna, Ellebedy, Davis, Jacob, Ahmed, Antia (bib17) 2015; 370 O'Brien, Forleo-Neto, Sarkar (bib32) 2022; 327 Bates, Leier, Lyski (bib4) 2021; 12 Nkolola, Yu, Wan (bib20) 2022; 14 Jackson, Anderson, Rouphael (bib26) 2020; 383 Portal-Celhay, Forleo-Neto, Eagan (bib23) 2022; 5 Anderson, Rouphael, Widge (bib25) 2020; 383 Feng, Phillips, White (bib9) 2021; 27 Hermens, Kesmir (bib30) 2023; 75 Andrews, Stowe, Kirsebom (bib31) 2022; 386 (bib7) 2022 Anderson (10.1016/S1473-3099(24)00421-3_bib25) 2020; 383 Gilbert (10.1016/S1473-3099(24)00421-3_bib27) 2022; 375 Bates (10.1016/S1473-3099(24)00421-3_bib4) 2021; 12 Zarnitsyna (10.1016/S1473-3099(24)00421-3_bib17) 2015; 370 Benkeser (10.1016/S1473-3099(24)00421-3_bib11) 2023; 15 Follmann (10.1016/S1473-3099(24)00421-3_bib10) 2023; 14 Montgomery (10.1016/S1473-3099(24)00421-3_bib14) 2022; 10 Cohen (10.1016/S1473-3099(24)00421-3_bib16) 2021; 326 (10.1016/S1473-3099(24)00421-3_bib7) 2022 Schaefer-Babajew (10.1016/S1473-3099(24)00421-3_bib21) 2023; 613 O'Brien (10.1016/S1473-3099(24)00421-3_bib32) 2022; 327 Hermens (10.1016/S1473-3099(24)00421-3_bib30) 2023; 75 Weinreich (10.1016/S1473-3099(24)00421-3_bib1) 2021; 385 (10.1016/S1473-3099(24)00421-3_bib22) 2022 Goel (10.1016/S1473-3099(24)00421-3_bib28) 2021; 6 Greaney (10.1016/S1473-3099(24)00421-3_bib3) 2021; 13 Levin (10.1016/S1473-3099(24)00421-3_bib12) 2022; 386 Hammond (10.1016/S1473-3099(24)00421-3_bib5) 2022; 386 Nkolola (10.1016/S1473-3099(24)00421-3_bib20) 2022; 14 Dougan (10.1016/S1473-3099(24)00421-3_bib15) 2021; 385 O'Brien (10.1016/S1473-3099(24)00421-3_bib13) 2022; 327 Feng (10.1016/S1473-3099(24)00421-3_bib9) 2021; 27 Andrews (10.1016/S1473-3099(24)00421-3_bib31) 2022; 386 (10.1016/S1473-3099(24)00421-3_bib6) 2021 Benschop (10.1016/S1473-3099(24)00421-3_bib19) 2022; 14 Jackson (10.1016/S1473-3099(24)00421-3_bib26) 2020; 383 Irvin (10.1016/S1473-3099(24)00421-3_bib24) 2021; 13 O'Brien (10.1016/S1473-3099(24)00421-3_bib2) 2021; 385 Portal-Celhay (10.1016/S1473-3099(24)00421-3_bib23) 2022; 5 (10.1016/S1473-3099(24)00421-3_bib8) 2021 Atmar (10.1016/S1473-3099(24)00421-3_bib29) 2022; 386 |
| References_xml | – volume: 327 start-page: 432 year: 2022 end-page: 441 ident: bib13 article-title: Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: a randomized clinical trial publication-title: JAMA – volume: 13 start-page: 1827 year: 2021 end-page: 1836 ident: bib24 article-title: REGEN-COV antibody cocktail bioanalytical strategy: comparison of LC-MRM-MS and immunoassay methods for drug quantification publication-title: Bioanalysis – year: 2022 ident: bib22 article-title: Emergency Use Authorization 091 – year: 2021 ident: bib6 article-title: Fact sheet for health care providers: Emergency Use Authorization (EUA) of REGEN-COV (casirivimab and imdevimab) – volume: 6 year: 2021 ident: bib28 article-title: Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination publication-title: Sci Immunol – volume: 385 start-page: 1184 year: 2021 end-page: 1195 ident: bib2 article-title: Subcutaneous REGEN-COV antibody combination to prevent COVID-19 publication-title: N Engl J Med – volume: 386 start-page: 2188 year: 2022 end-page: 2200 ident: bib12 article-title: Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of COVID-19 publication-title: N Engl J Med – year: Feb 4, 2022 ident: bib18 article-title: Updates to interim clinical considerations for use of COVID-19 vaccines – volume: 386 start-page: 1532 year: 2022 end-page: 1546 ident: bib31 article-title: COVID-19 vaccine effectiveness against the omicron (B.1.1.529) variant publication-title: N Engl J Med – volume: 383 start-page: 1920 year: 2020 end-page: 1931 ident: bib26 article-title: An mRNA vaccine against SARS-CoV-2—preliminary report publication-title: N Engl J Med – volume: 27 start-page: 2032 year: 2021 end-page: 2040 ident: bib9 article-title: Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection publication-title: Nat Med – volume: 385 start-page: 1382 year: 2021 end-page: 1392 ident: bib15 article-title: Bamlanivimab plus etesevimab in mild or moderate COVID-19 publication-title: N Engl J Med – volume: 15 year: 2023 ident: bib11 article-title: Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial publication-title: Sci Transl Med – volume: 14 year: 2022 ident: bib19 article-title: The anti-SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination publication-title: Sci Transl Med – volume: 386 start-page: 1397 year: 2022 end-page: 1408 ident: bib5 article-title: Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19 publication-title: N Engl J Med – volume: 75 start-page: 295 year: 2023 end-page: 307 ident: bib30 article-title: Role of T cells in severe COVID-19 disease, protection, and long term immunity publication-title: Immunogenetics – year: 2022 ident: bib7 article-title: Fact sheet for health care providers: Emergency Use Authorization (EUA) of bamlanivimab and etesevimab – volume: 5 year: 2022 ident: bib23 article-title: Virologic efficacy of casirivimab and imdevimab COVID-19 antibody combination in outpatients with SARS-CoV-2 infection: a phase 2 dose-ranging randomized clinical trial publication-title: JAMA Netw Open – volume: 386 start-page: 1046 year: 2022 end-page: 1057 ident: bib29 article-title: Homologous and heterologous COVID-19 booster vaccinations publication-title: N Engl J Med – volume: 327 start-page: 432 year: 2022 end-page: 441 ident: bib32 article-title: Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: a randomized clinical trial publication-title: JAMA – volume: 13 year: 2021 ident: bib3 article-title: Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection publication-title: Sci Transl Med – volume: 385 start-page: e81 year: 2021 ident: bib1 article-title: REGEN-COV antibody combination and outcomes in outpatients with COVID-19 publication-title: N Engl J Med – volume: 370 year: 2015 ident: bib17 article-title: Masking of antigenic epitopes by antibodies shapes the humoral immune response to influenza publication-title: Philos Trans R Soc Lond B Biol Sci – year: 2021 ident: bib8 article-title: Fact sheet for healthcare providers: Emergency Use Authorization for Evusheld (tixagevimab co-packaged with cilgavimab) – volume: 10 start-page: 985 year: 2022 end-page: 996 ident: bib14 article-title: Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial publication-title: Lancet Respir Med – volume: 375 start-page: 43 year: 2022 end-page: 50 ident: bib27 article-title: Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial publication-title: Science – volume: 12 year: 2021 ident: bib4 article-title: Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum publication-title: Nat Commun – volume: 613 start-page: 735 year: 2023 end-page: 742 ident: bib21 article-title: Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination publication-title: Nature – volume: 14 year: 2022 ident: bib20 article-title: A bivalent SARS-CoV-2 monoclonal antibody combination does not affect the immunogenicity of a vector-based COVID-19 vaccine in macaques publication-title: Sci Transl Med – volume: 14 year: 2023 ident: bib10 article-title: Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration publication-title: Nat Commun – volume: 326 start-page: 46 year: 2021 end-page: 55 ident: bib16 article-title: Effect of bamlanivimab vs placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities: a randomized clinical trial publication-title: JAMA – volume: 383 start-page: 2427 year: 2020 end-page: 2438 ident: bib25 article-title: Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults publication-title: N Engl J Med – volume: 386 start-page: 2188 year: 2022 ident: 10.1016/S1473-3099(24)00421-3_bib12 article-title: Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of COVID-19 publication-title: N Engl J Med doi: 10.1056/NEJMoa2116620 – volume: 14 year: 2022 ident: 10.1016/S1473-3099(24)00421-3_bib19 article-title: The anti-SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination publication-title: Sci Transl Med doi: 10.1126/scitranslmed.abn3041 – year: 2021 ident: 10.1016/S1473-3099(24)00421-3_bib6 – volume: 27 start-page: 2032 year: 2021 ident: 10.1016/S1473-3099(24)00421-3_bib9 article-title: Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection publication-title: Nat Med doi: 10.1038/s41591-021-01540-1 – volume: 14 year: 2022 ident: 10.1016/S1473-3099(24)00421-3_bib20 article-title: A bivalent SARS-CoV-2 monoclonal antibody combination does not affect the immunogenicity of a vector-based COVID-19 vaccine in macaques publication-title: Sci Transl Med doi: 10.1126/scitranslmed.abo6160 – volume: 75 start-page: 295 year: 2023 ident: 10.1016/S1473-3099(24)00421-3_bib30 article-title: Role of T cells in severe COVID-19 disease, protection, and long term immunity publication-title: Immunogenetics doi: 10.1007/s00251-023-01294-9 – volume: 375 start-page: 43 year: 2022 ident: 10.1016/S1473-3099(24)00421-3_bib27 article-title: Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial publication-title: Science doi: 10.1126/science.abm3425 – volume: 10 start-page: 985 year: 2022 ident: 10.1016/S1473-3099(24)00421-3_bib14 article-title: Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(22)00180-1 – volume: 370 year: 2015 ident: 10.1016/S1473-3099(24)00421-3_bib17 article-title: Masking of antigenic epitopes by antibodies shapes the humoral immune response to influenza publication-title: Philos Trans R Soc Lond B Biol Sci doi: 10.1098/rstb.2014.0248 – volume: 5 year: 2022 ident: 10.1016/S1473-3099(24)00421-3_bib23 article-title: Virologic efficacy of casirivimab and imdevimab COVID-19 antibody combination in outpatients with SARS-CoV-2 infection: a phase 2 dose-ranging randomized clinical trial publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2022.25411 – volume: 385 start-page: 1382 year: 2021 ident: 10.1016/S1473-3099(24)00421-3_bib15 article-title: Bamlanivimab plus etesevimab in mild or moderate COVID-19 publication-title: N Engl J Med doi: 10.1056/NEJMoa2102685 – volume: 383 start-page: 2427 year: 2020 ident: 10.1016/S1473-3099(24)00421-3_bib25 article-title: Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults publication-title: N Engl J Med doi: 10.1056/NEJMoa2028436 – volume: 386 start-page: 1046 year: 2022 ident: 10.1016/S1473-3099(24)00421-3_bib29 article-title: Homologous and heterologous COVID-19 booster vaccinations publication-title: N Engl J Med doi: 10.1056/NEJMoa2116414 – volume: 13 year: 2021 ident: 10.1016/S1473-3099(24)00421-3_bib3 article-title: Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection publication-title: Sci Transl Med doi: 10.1126/scitranslmed.abi9915 – volume: 327 start-page: 432 year: 2022 ident: 10.1016/S1473-3099(24)00421-3_bib13 article-title: Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: a randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2021.24939 – volume: 327 start-page: 432 year: 2022 ident: 10.1016/S1473-3099(24)00421-3_bib32 article-title: Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: a randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2021.24939 – volume: 14 year: 2023 ident: 10.1016/S1473-3099(24)00421-3_bib10 article-title: Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration publication-title: Nat Commun doi: 10.1038/s41467-023-39292-w – volume: 13 start-page: 1827 year: 2021 ident: 10.1016/S1473-3099(24)00421-3_bib24 article-title: REGEN-COV antibody cocktail bioanalytical strategy: comparison of LC-MRM-MS and immunoassay methods for drug quantification publication-title: Bioanalysis doi: 10.4155/bio-2021-0190 – volume: 386 start-page: 1397 year: 2022 ident: 10.1016/S1473-3099(24)00421-3_bib5 article-title: Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19 publication-title: N Engl J Med doi: 10.1056/NEJMoa2118542 – volume: 385 start-page: 1184 year: 2021 ident: 10.1016/S1473-3099(24)00421-3_bib2 article-title: Subcutaneous REGEN-COV antibody combination to prevent COVID-19 publication-title: N Engl J Med doi: 10.1056/NEJMoa2109682 – year: 2021 ident: 10.1016/S1473-3099(24)00421-3_bib8 – year: 2022 ident: 10.1016/S1473-3099(24)00421-3_bib22 – volume: 15 year: 2023 ident: 10.1016/S1473-3099(24)00421-3_bib11 article-title: Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial publication-title: Sci Transl Med doi: 10.1126/scitranslmed.ade9078 – volume: 383 start-page: 1920 year: 2020 ident: 10.1016/S1473-3099(24)00421-3_bib26 article-title: An mRNA vaccine against SARS-CoV-2—preliminary report publication-title: N Engl J Med doi: 10.1056/NEJMoa2022483 – volume: 6 year: 2021 ident: 10.1016/S1473-3099(24)00421-3_bib28 article-title: Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination publication-title: Sci Immunol doi: 10.1126/sciimmunol.abi6950 – volume: 613 start-page: 735 year: 2023 ident: 10.1016/S1473-3099(24)00421-3_bib21 article-title: Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination publication-title: Nature doi: 10.1038/s41586-022-05609-w – volume: 386 start-page: 1532 year: 2022 ident: 10.1016/S1473-3099(24)00421-3_bib31 article-title: COVID-19 vaccine effectiveness against the omicron (B.1.1.529) variant publication-title: N Engl J Med doi: 10.1056/NEJMoa2119451 – volume: 385 start-page: e81 year: 2021 ident: 10.1016/S1473-3099(24)00421-3_bib1 article-title: REGEN-COV antibody combination and outcomes in outpatients with COVID-19 publication-title: N Engl J Med doi: 10.1056/NEJMoa2108163 – volume: 326 start-page: 46 year: 2021 ident: 10.1016/S1473-3099(24)00421-3_bib16 article-title: Effect of bamlanivimab vs placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities: a randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2021.8828 – volume: 12 year: 2021 ident: 10.1016/S1473-3099(24)00421-3_bib4 article-title: Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum publication-title: Nat Commun doi: 10.1038/s41467-021-25479-6 – year: 2022 ident: 10.1016/S1473-3099(24)00421-3_bib7 |
| SSID | ssj0017104 |
| Score | 2.4830935 |
| Snippet | Deeper insight is needed on how monoclonal antibodies (mAbs) affect vaccine-mediated immune responses when targeting the same protein. We describe the first... Summary Background Deeper insight is needed on how monoclonal antibodies (mAbs) affect vaccine-mediated immune responses when targeting the same protein. We... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 52 |
| SubjectTerms | 2019-nCoV Vaccine mRNA-1273 Adult Adverse events Aged Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - immunology Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - immunology Antibodies, Neutralizing - blood Antibodies, Viral - blood Blood COVID-19 COVID-19 - immunology COVID-19 - prevention & control COVID-19 vaccines COVID-19 Vaccines - administration & dosage COVID-19 Vaccines - adverse effects COVID-19 Vaccines - immunology Dilution Disease prevention Epitopes Female Health services Humans Immune response Immune system Immunity (Disease) Infectious diseases Intravenous administration Labels Lymphocytes B Lymphocytes T Male Middle Aged Monoclonal antibodies mRNA Prospective Studies Proteins Public health Randomization Safety analysis SARS-CoV-2 - immunology Severe acute respiratory syndrome coronavirus 2 Spike Glycoprotein, Coronavirus - immunology Spike protein Vaccination - methods Vaccines Viral diseases |
| Title | Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1473309924004213 https://dx.doi.org/10.1016/S1473-3099(24)00421-3 https://www.ncbi.nlm.nih.gov/pubmed/39236733 https://www.proquest.com/docview/3149695428 https://www.proquest.com/docview/3101230055 |
| Volume | 25 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1di9NAFB10F0QQ0fWrui4j-KDQcU1mkkl8kVp3WYWt0rpL38J83GigTeo2LfiH_R3eSSZZfFhXCCVpcieEOZl7cufOPYS8lAZ4DmHMrADNhEmUk3lJmUljAK1ELpt4x-kkPjkTn-fR3Afc1j6tshsTm4HaVsbFyA85Uvk4jZAtv1_9ZE41ys2uegmNm2TXlS5zKV1y3n9wBeg9m1llITnjSIUuV_Aczvo_X4XitYNuwPhVvukq7tn4oON75K4nj3TU9vZ9cgPKPXLr1E-P75E7bRCOtmuLHpDfbW1iWuW0dupd392eUeviotgWS6WpKi0tlhb80V-FdGm7zGULtK7ocjoZsQBJCB1_Of_0kQUp3SqDd20vxa09BIbf-IgWS2ej6YyNq3MW0hI2TTzFhSXwlnWhK_sLm2-yc2H9jiqKj96t-RxSp-jFEJ2wGNLVD3SzNBxS9Km2QlBi0z69foG7jejIQ3J2fPRtfMK8sAMzQsiaCSulTbSBUFgVWxtoZG0pBEpHCUS5jUOrlIAQjE41BMZJIisAqfI8yhMp-SOyU1YlPCE0RSOVWp5IrYV8a3VgdC4DHXEb5UYkAyK6Ls2Mr3ruxDcWWZ_e5pCQOSRkocgaJGR8QN70Zqu27Md1BnGHl6xb04qjcIaO6TrDpDf0pKclM_9jut8BM_Mjzzq7fE8G5EV_GrvHTQSpEqqNu8YxaVd-bUAet4DunxL5Mo8l50__3fgzcjt0SshNMGqf7NQXG3iO9KzWB807iL_JODggux-OJl-nfwDYqjhz |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1tb9MwELZGJwESQjAYFAYYCSSQakZiJ06QECrdppatBbXbtG_Bb4FIbVLWtGh_ip_F7-Cct4kPY3yZ1A9JmnMU-c735M53D0IvuDI0Nq5PNDOSMBUIS_MSEhX6xkjBYl7EO4Yjv3_EPp14J2voV10LY7dV1mtisVDrTNkY-TYFKO-HHqDlD_MfxLJG2exqTaFRqsW-OfsJn2yL94MdmN-Xrru3e9jrk4pVgCjGeE6Y5lwHUhmXaeFr7UiADKFxhPQC48Xad7UQzLhGyVAaR1k-XmEMF3HsxQHnFMa9htYZhU-ZFlr_uDv6Mm7yFuCvizw245RQAF_nNUPbk-biK5e9tsbiEHqRN7wI7RZeb-8Oul3BVdwt9esuWjPpBro-rBLyG-hWGfbDZTXTPfS77IaMsxjnli_smz1SYpGcJqtkJiQWqcbJTJvq7K_WvbgsrFkZnGd4Nh51iQOwB_c-Hw92iBPilVDw1PJW-JWnhiSpBv3UeNIdT0gvOyYuTs2yiODYQAg8Mk9kps9g-GI_sFm8wwLDq9dVph1sOcQI2IOZdvD8Ozh27HYweHGdgRnA0NWG_ikcFjQn99HRlUz6JmqlWWoeIhyCkAg1DbiUjL_V0lEy5o70qPZixYI2YvWURqrqs27pPqZRs6HOakJkNSFyWVRoQkTb6E0jNi8bjVwm4Nf6EtVVtLDuR-AKLxMMGsEKZpXw6X9Et2rFjKq1bhGdW2YbPW_-humxqSeRmmxp77HY3TZ8a6MHpUI3bwkInfqc0kf_HvwZutE_HB5EB4PR_mN007U8zEUobAu18tOleQLgMJdPK4vE6OtVLwJ_AEKVd5E |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbtNAEF2VIlVICEG5BQosEkggZQn2rr02EkJRQtRQGlBLq7yZvYwhUmKH5oL6a3wQ38GsbxUPpbxUyoPteNaydmbneHZmDiHPpAGegh8yK0AzYSLlaF5iZuIQQCuRyiLesT8Kd4_Eh3Ew3iC_6loYl1ZZr4nFQm1z42LkHY5QPowDRMudtEqL-NwfvJv_YI5Byu201nQapYrswelP_HxbvB32ca6f-_7g_ZfeLqsYBpgRQi6ZsFLaSBvwhVWhtZ5G-BCDp3QQQZDa0LdKCfDB6FiDZxw3rwKQKk2DNJKS47hXyFXJA8_ZmBw3H3seeu5iR1tIzjjCsLPqoc5hc_GFL146s_EYP88vnod7C_83uEluVMCVdktNu0U2INsmW_vV1vw2uV4GAGlZ13Sb_C77ItM8pUvHHPbNHRm1mJxM1pOZ0lRllk5mFqqzv5r40rLEZg10mdPZwajLPARAtPfpeNhnXkzXyuBTy1vxV54Cm2QWNdXSw-7BIevlx8ynGayKWI4LieAjlxOd21McvsgMhsUbqii-el1v2qaOTYyhZcC0Teff0cVTv03Rn9scDQKHrlL7p3hYEJ7cIUeXMuV3yWaWZ3Cf0BiFVGx5JLUW8rXVntGp9HTAbZAaEbWIqKc0MVXHdUf8MU2a1DqnCYnThMQXSaEJCW-RV43YvGw5cpFAWOtLUtfTogdI0CleJBg1ghXgKoHU_4ju1IqZVKveIjmz0RZ52vyN0-M2oVQG-crd41C8a_3WIvdKhW7eErE6DyXnD_49-BOyhaaffByO9h6Sa74jZC5iYjtkc3mygkeIEpf6cWGOlHy9bPv_A4PvemE |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+timing+of+casirivimab+and+imdevimab+administration+relative+to+mRNA-1273+COVID-19+vaccination+on+vaccine-induced+SARS-CoV-2+neutralising+antibody+responses%3A+a+prospective%2C+open-label%2C+phase+2%2C+randomised+controlled+trial&rft.jtitle=The+Lancet+infectious+diseases&rft.au=Isa%2C+Flonza&rft.au=Gonzalez+Ortiz%2C+Ana+M&rft.au=Meyer%2C+Jonathan&rft.au=Hamilton%2C+Jennifer+D&rft.date=2025-01-01&rft.pub=Elsevier+Limited&rft.issn=1473-3099&rft.eissn=1474-4457&rft.volume=25&rft.issue=1&rft.spage=52&rft_id=info:doi/10.1016%2FS1473-3099%2824%2900421-3&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1473-3099&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1473-3099&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1473-3099&client=summon |